4. The use of any one of claims 1-3, wherein the melanoma in the individual has progressed within 1 month, 6 months, 1 year, or 5 years after completing a B-raf antagonist-based therapy regimen.

5. The use of any one of claims 1-4, wherein the melanoma contains a BRAF V600E mutation.

6. The use of any one of claims 1-5, wherein the treatment results in a sustained response in the individual after cessation of the treatment.

7. The use of any one of claims 1-6, wherein the melanoma is metastatic.

8. The use of any one of claims 1-7, wherein the PD-L1 antagonist inhibits the binding of PD-L1 to PD-1, PD-L1 to B7-1, or PD-L1 to both PD-1 and B7-1.

9. The use of any one of claims 1-8, wherein the anti-PD-L1 antibody is a monoclonal antibody.

10. The use of any one of claims 1-8, wherein the anti-PD-L1 antibody is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and $(Fab')_2$ fragments.

11. The use of any one of claims 1-10, wherein the anti-PD-L1 antibody is a humanized antibody or a human antibody.

12. The use of any one of claims 1-9 and 11, wherein the anti-PD-L1 antibody is selected from the group consisting of: YW243.55.S70, atezolizumab, durvalumab, MDX-1105, and avelumab.

13. The use of any one of claims 1-12, wherein the antibody comprises a heavy chain comprising HVR-H1 sequence of SEQ ID NO:15, HVR-H2 sequence of SEQ ID NO:16, and HVR-H3 sequence of SEQ ID NO:3; and a light chain comprising HVR-L1 sequence of SEQ ID NO:17, HVR-L2 sequence of SEQ ID NO:18, and HVR-L3 sequence of SEQ ID NO:19.

14. The use of any one of claims 1-12, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:24 or SEQ ID NO:28 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:21.

15. The use of any one of claims 1-14, wherein the MEK inhibitor is to be administered continuously.

16. The use of any one of claims 1-14, wherein the MEK inhibitor is to be administered intermittently.

17. The use of any one of claims 1-14, wherein the MEK inhibitor is to be administered before the PD-L1 antagonist.

18. The use of any one of claims 1-14, wherein the MEK inhibitor is to be administered